If a "buyout" occurs, which is highly likely and the reason we are even here now, then we are gone, the lot of us. No company is going to buy a salesforce, they want the drug and the expanded indications NOT THE SALES REPS. The last thing any company needs is reps! We are here to pad the spreadsheets for the investors to see "penetration", so Krystexxa looks better on paper, they had to have a temporary sales force at least attempt to sell this and they are using us like pawns for metric reports. But that was part of the deal, I am not complaining, I use them just as they use me. Part of the game, this industry is not what it was 10 years ago. It is all about making it look good on paper for the street and hope that another big pharma swoops in and over pays on the stock and makes the board and CEO rich, and we will be tossed like yesterdays news in a heartbeat. That is how this works. Most of us have been through this before, many times.